Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2021-10-26 Regulatory Filings
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Registration Statement number and the Securities Act of 1933. The content is a formal correspondence related to the registration process for securities, not the registration statement itself or a financial report. The document length is short (1729 characters) and it is a communication about the filing process rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with regulatory bodies that do not fit other categories.
2021-10-26 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for 4D Molecular Therapeutics, Inc. It is a detailed registration statement under the Securities Act of 1933, used for initial public offerings or other securities offerings. The text includes the SEC header, registration number, company details, offering details, underwriting information, and a prospectus summary. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to the registration of securities for public sale. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-10-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content focuses on clinical trial interim data updates for drug candidates, describing patient enrollment, safety, and efficacy data. It does not contain comprehensive financial statements or annual/quarterly financial results. It is not an earnings release, annual report, or interim report. The document is not a proxy, governance, or management change announcement. It is a regulatory filing reporting clinical trial progress and other material events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement or certification.
2021-10-26 English
FORM 4
Director's Dealing
2021-10-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on announcing interim clinical trial data and safety results for a drug candidate, 4D-125, including detailed clinical activity and safety summaries. There are no full financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is not a transcript, proxy, or governance report. It is a regulatory announcement of clinical trial progress and other material events, fitting the category of a Regulatory Filing (RNS) as it does not fit other specific categories and is a general regulatory announcement under SEC rules.
2021-10-13 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible structured content, titles, or keywords related to any specific financial filing type. There are no references to regulatory bodies, report titles, fiscal periods, or any typical financial or corporate disclosure language. The document length is 15,000 characters, which is substantial, but the content does not contain meaningful text to classify as a report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a catch-all category for filings that do not fit other specific categories.
2021-10-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.